Project Grant R01HL184900
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $787K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $1,357,964 on August 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to discover prognostic biomarkers of early pulmonary fibrosis and develop secondary prevention strategies. The research identifies genetic, molecular, and environmental biomarkers that trigger and predict progression of fibrotic interstitial lung abnormalities (FILAs)...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $676,602 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of LYVE1-expressing interstitial macrophage-driven vascular remodeling in pulmonary hypertension. The research examines the role of LYVE1+ interstitial macrophages (IMs) in pulmonary hypertension, a deadly, incurable disease of the pulmonary...
- The National Heart, Lung, and Blood Institute awarded $753,907 to the University of Vermont & State Agricultural College on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of ovarian tumor deubiquitinase 1 (OTUB1) in idiopathic pulmonary fibrosis pathogenesis. The research examines how aberrant differentiation of lung epithelial cells contributes to IPF, specifically how OTUB1 glutathione-conjugation augments non-canonical signaling...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,097,760 on February 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund a Project Grant (R35HL183538) investigating mechanisms of age-related pulmonary fibrosis and lung regeneration. The research program addresses idiopathic pulmonary fibrosis (IPF), a progressive disease affecting approximately 200,000 patients annually in the United States with...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $212,782 on September 9, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate developmental dysanapsis in lung development throughout the lifespan in experimental bronchopulmonary dysplasia. The research examines whether intra-amniotic endotoxin causes persistent dysanaptic growth of airways, distal parenchyma, and...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $572,539 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define histone deacetylase 8 (HDAC8) regulation of cardiac myofilament relaxation. The research addresses diastolic dysfunction, which is characterized by slower cardiac relaxation and has proven difficult to treat pharmacologically due to complexity...
- The National Institutes of Health National Heart Lung and Blood Institute awarded $150,104 to The Regents Of The University Of Colorado (University of Colorado-Denver) on January 26, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for a Project Grant (F32HL179804) to investigate lysine myristoylation as a regulatory mechanism for protein kinase A (PKA) in cardiac tissue. The award funds research examining how histone deacetylase 11 (HDAC11) inhibition increases PKA...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $746,392 in project grant funding on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to delineate ventilator-induced lung injury arising from specific types of ventilator dyssynchrony—double-triggered, flow-limited, and ineffective-triggered breaths. The research addresses the gap in understanding dose-response relationships between...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $766,557 for a Project Grant (R01HL188011) on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into bronchiolization—the takeover of alveoli by airway cell types—a hallmark of interstitial lung diseases including idiopathic pulmonary fibrosis. The project uses CRISPR/Cas9 genome editing to generate mouse models carrying patient mutations in...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $249,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 2, 2026, to support research on the role of subpleural fibroblasts in pulmonary fibrosis progression. The funded research investigates idiopathic pulmonary fibrosis (IPF), which begins with scar tissue buildup at the lung edges and advances centrally. The project applies lineage tracing, mouse modeling, and...